FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 337:1228-1229 October 23, 1997 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

The development of the quadrivalent rotavirus vaccine evaluated in the study by Pérez-Schael et al., reported in this issue of the Journal,¹ represents the culmination of a long and highly creative process of research and development at the National Institutes of Health.² Today, just 25 years after rotavirus was discovered,³ the use of a modified Jennerian approach has resulted in a quadrivalent vaccine that combines a naturally attenuated serotype 3 rhesus rotavirus with reassortants composed of 10 genomic segments of rhesus rotavirus RNA plus 1 of human origin encoding the VP7 neutralization specificity of serotype 1, 2, or 4 rotavirus.⁴ . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Chen, S. C., Jones, D. H., Fynan, E. F., Farrar, G. H., Clegg, J. C. S., Greenberg, H. B., Herrmann, J. E. (1998). Protective Immunity Induced by Oral Immunization with a Rotavirus DNA Vaccine Encapsulated in Microparticles. J. Virol. 72: 5757-5761 [Abstract] [Full Text]  
• O'Ryan, M. L., Matson, D. O., Davidson, B. L., Keusch, G. T., Cash, R. A. (1998). A Quadrivalent Rotavirus Vaccine. NEJM 338: 620-622 [Full Text]